These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1102452)

  • 1. Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin.
    Lavillaureix J; Brogard JM; Pinget M; Ledoux F
    Infection; 1975; 3(2):105-14. PubMed ID: 1102452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefazolin in patients with renal failure; special reference to hemodialysis.
    Brogard JM; Pinget M; Brandt C; Lavillaureix J
    J Clin Pharmacol; 1977 Apr; 17(4):225-30. PubMed ID: 849996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjustment of cephaloridine (Keflodin): dosage according to its pharmacokinetics.
    Brogard JM; Brandt C; Dorner M; Dammron A
    Chemotherapy; 1976; 22(1):1-11. PubMed ID: 1253626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cephacetrile--application of pharmacokinetic data to dosage determination.
    Brogard JM; Dorner M; Brandt C; Lavillaureix J
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):168-76. PubMed ID: 950258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Pinget M; Dorner M; Lavillaureix J
    J Clin Pharmacol; 1975 Oct; 15(10):666-73. PubMed ID: 1184770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Kopferschmitt J; Spach MO; Grudet O; Lavillaureix J
    J Clin Pharmacol; 1979 Jul; 19(7):366-77. PubMed ID: 479381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefazolin in children with renal insufficiency.
    Hiner LB; Baluarte HJ; Polinsky MS; Gruskin AB
    J Pediatr; 1980 Feb; 96(2):335-9. PubMed ID: 7351609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.
    Smyth RD; Pfeffer M; Glick A; Van Harken DR; Hottendorf GH
    Antimicrob Agents Chemother; 1979 Nov; 16(5):615-21. PubMed ID: 526003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.
    Sowinski KM; Mueller BA; Grabe DW; Manley HJ; Frye RF; Bailie GR; Marx MA
    Am J Kidney Dis; 2001 Apr; 37(4):766-76. PubMed ID: 11273877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.
    Philipson A; Stiernstedt G; Ehrnebo M
    Clin Pharmacokinet; 1987 Feb; 12(2):136-44. PubMed ID: 3829560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin.
    Harvengt C; Muenier H; Lamy F
    J Clin Pharmacol; 1977; 17(2-3):128-33. PubMed ID: 833342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
    Lee FH; Pfeffer M; Van Harken DR; Smyth RD; Hottendorf GH
    Antimicrob Agents Chemother; 1980 Feb; 17(2):188-92. PubMed ID: 7387141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function.
    Brogard JM; Comte F; Spach MO; Lavillaureix J
    Chemotherapy; 1982; 28(5):318-26. PubMed ID: 6216076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, distribution and elimination of cefazolin in patients with normal renal function.
    Bergan T; Digranes A; Schreiner A
    Chemotherapy; 1978; 24(5):277-82. PubMed ID: 352636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum half-life and urine concentrations of cephazolin sodium in patients with terminal renal failure: effect of haemodialysis.
    Eastwood JB; Gower PE; Curtis JR
    Scott Med J; 1976 Sep; 20(5):240-3. PubMed ID: 1265473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of cefazolin in the presence of normal and impaired renal function.
    Rein MF; Westervelt FB; Sande MA
    Antimicrob Agents Chemother; 1973 Sep; 4(3):366-71. PubMed ID: 4758839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of infections with cefazolin.
    Schreiner A; Digranes A; Hamre E; Nygaard H
    Chemotherapy; 1976; 22(6):381-9. PubMed ID: 821726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five cephalosporins: pharmacokinetics and their relation to antibacterial potency.
    Sohn C; Pitkin D; Grappel S; Zajac I; Actor P; Alexander F; Lentnek A; Wikler M; Stote R; Dubb J
    Clin Ther; 1984; 6(4):560-70. PubMed ID: 6467282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis.
    Palmer K; Walker S; Richardson R; Jassal SV; Battistella M
    Ann Pharmacother; 2019 Apr; 53(4):348-356. PubMed ID: 30345801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.